Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Kaletra?
Oct 6, 2003

Dr. Wohl, in your practice what would you recommend for treatment experienced patients who are resistant to Sustiva and need a PI - boosted reyataz or kaletra? I know the reyataz would have less cholesterol issues, but I'm worried that it might not be as effective as kaletra in controlling the virus. Thanks for all of your help! Dave

Response from Dr. Wohl

Treatment options for the multi-drug experienced patient are increasing. While Kaletra has been included in salvage regimens since it came on the market, recent data suggests that ritonavir boosted atazanavir may be comparable in this situation. In a study of over 350 people with extensive antiretroviral experience, a median CD4 of 300 and a median viral load of 30,000 were randomized to once a day atazanavir 300 mg + ritonavir 100 mg vs twice a day Kaletra (lopinavir + ritonavor) vs once daily atazanavir 400 mg + saquinavir 1200 mg. Bottom line was the atazanavir/ritonavir and the Kaletra arms did better in suppressing viral loads below 50 copies over 6 months (~40%)compared to the other arm (~23%). There may have been a trend favoring Kaletra but lipids were unsurprisingly better in the boosted atazanavir arm. These were 24 week data so longer term follow-up will be important. More on this study can be found at: http://www.thebodypro.com/confs/ias2003/cohen2.html

Another advance for salvage will be tipranavir, a new protease inhibitor that also needs ritonavir boosting and is in expanded access now.

At this point, there are more data and experience supporting Kaletra but I think boosted atazanavir remains an option in this situation especially because the leading cause of treatment failure is probably suboptimal adherence. A regimen with fewer pills and less frequent dosing may lead to more adherence and maybe better results for those who tend to miss doses. Note, the temptation to use tenofovir with azatanavir, even when boosted with ritonavir, has to be tempered by the reduction in atazanavir levels seen when these once a day drugs are combined. DW



Previous
Wohl, I gotta proposition for ya
Next
recombitant human growth horrnone

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement